Back to Search Start Over

Information fraction estimation: Strategies for a phase 3 non-inferiority maximum duration design with time to event outcome.

Authors :
Dang HM
Krailo MD
Alonzo TA
Mack WJ
Kairalla JA
Source :
Pharmaceutical statistics [Pharm Stat] 2023 Nov-Dec; Vol. 22 (6), pp. 1031-1045. Date of Electronic Publication: 2023 Jul 26.
Publication Year :
2023

Abstract

There is considerable debate surrounding the choice of methods to estimate information fraction for futility monitoring in a randomized non-inferiority maximum duration trial. This question was motivated by a pediatric oncology study that aimed to establish non-inferiority for two primary outcomes. While non-inferiority was determined for one outcome, the futility monitoring of the other outcome failed to stop the trial early, despite accumulating evidence of inferiority. For a one-sided trial design for which the intervention is inferior to the standard therapy, futility monitoring should provide the opportunity to terminate the trial early. Our research focuses on the Total Control Only (TCO) method, which is defined as a ratio of observed events to total events exclusively within the standard treatment regimen. We investigate its properties in stopping a trial early in favor of inferiority. Simulation results comparing the TCO method with alternative methods, one based on the assumption of an inferior treatment effect (TH0), and the other based on a specified hypothesis of a non-inferior treatment effect (THA), were provided under various pediatric oncology trial design settings. The TCO method is the only method that provides unbiased information fraction estimates regardless of the hypothesis assumptions and exhibits a good power and a comparable type I error rate at each interim analysis compared to other methods. Although none of the methods is uniformly superior on all criteria, the TCO method possesses favorable characteristics, making it a compelling choice for estimating the information fraction when the aim is to reduce cancer treatment-related adverse outcomes.<br /> (© 2023 John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
1539-1612
Volume :
22
Issue :
6
Database :
MEDLINE
Journal :
Pharmaceutical statistics
Publication Type :
Academic Journal
Accession number :
37496113
Full Text :
https://doi.org/10.1002/pst.2327